Immunotherapy

You have access
Stratification by PD-L1 TPS in Advanced NSCLC With Low PD-L1 Expression for Optimizing Immunotherapy
TAKAFUMI FUKUI, SUYA HORI, YUKIHISA HATAKEYAMA, TATSUNORI KIRIU, KANOKO MATSUMURA, NANAKO MIWA, MASAHIRO KATSURADA, KEIKO OKUNO, SHO YOSHIMURA and MOTOKO TACHIHARA

Anticancer Research September 2025, 45 (9) 3859-3875; DOI: https://doi.org/10.21873/anticanres.17745
You have access
Nucleoporin 188 as a Predictive Biomarker of Poor Prognosis in Muscle-invasive Bladder Cancer
MINGXING ZHENG, JIANMING LU, WENSHI YU, YAXIAN LI, YONGLU WU, YUHUI YAO, HUIZHEN TIAN, LIANGLIANG HUANG, LE ZHANG and JUNHONG DENG

Anticancer Research August 2025, 45 (8) 3245-3261; DOI: https://doi.org/10.21873/anticanres.17686
Open Access
Immunotherapy and Chemotherapy for Advanced or Recurrent Endometrial Carcinoma
JOHN P. MICHA, RANDY D. BOHART, JOSHUA P. GORMAN and BRAM H. GOLDSTEIN

Anticancer Research July 2025, 45 (7) 2711-2717; DOI: https://doi.org/10.21873/anticanres.17641
You have access
Does Aggressive Versus Less Aggressive Non-operative Treatment of Large and Very Large (≥7 cm) Lung Cancers Matter?
FEDERICO AMPIL, CARLOS PREVIGLIANO, KIM HEATH and AMY BOZEMAN

Anticancer Research April 2025, 45 (4) 1593-1598; DOI: https://doi.org/10.21873/anticanres.17540
You have access
Comparative Analysis of Outcomes for Patients With Advanced Renal Cell Carcinoma: Immuno-Oncology Era Versus Tyrosine Kinase Inhibitor Era in the IMDC Favorable-risk Group
HIROKI ISHIHARA, YUKI NEMOTO, SHINSUKE MIZOGUCHI, KOICHI NISHIMURA, HIRONORI FUKUDA, KAZUHIKO YOSHIDA, HIROAKI SHIMMURA, YASUNOBU HASHIMOTO, JUNPEI IIZUKA, TSUNENORI KONDO and TOSHIO TAKAGI

Anticancer Research April 2025, 45 (4) 1643-1652; DOI: https://doi.org/10.21873/anticanres.17545
You have access
¹⁸F-Fluorocholine PET/CT as an Imaging Biomarker in Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab
WONSEOK WHI, HYUNJONG LEE, JUNG YONG HONG, WONSEOK KANG, YOUNG SEOK CHO, SEUNG HWAN MOON, JOON YOUNG CHOI, KYUNG-HAN LEE and SEUNG HYUP HYUN

Anticancer Research March 2025, 45 (3) 1273-1280; DOI: https://doi.org/10.21873/anticanres.17514
You have access
A New PD-L1 Nanobody Enhances Cell Death in Lung Cancer In Vitro and In Vivo
XIAO-TONG TAN, SHI-WEI HUANG, YU-CHUAN LIN, FANG-YU LIN, DER-YANG CHO and SHAO-CHIH CHIU

Anticancer Research February 2025, 45 (2) 535-547; DOI: https://doi.org/10.21873/anticanres.17442
Open Access
Unusual Presentation of Advanced Urothelial Cancer in a Young Patient
DANIELA GUEVARA, NARA SHIN, ALEXANDRA BOIKO, IVAN VALIEV, AHMED G. ELSAEED, JUAN MIGUEL MOSQUERA, MAJD AL ASSAAD, JYOTHI MANOHAR, MICHAEL SIGOUROS, ALISA ZAICHIKOVA, VICTORIA FOMCHENKOVA, LEYSAN YUNUSOVA, SOFIA SMIRNOVA, OLIVIER ELEMENTO, DAVID NANUS and CORA N. STERNBERG

Anticancer Research February 2025, 45 (2) 613-618; DOI: https://doi.org/10.21873/anticanres.17448
Open Access
Understanding the Genomic Landscape of Glioblastoma: Opportunities for Targeted Therapies
SABRINA L. ZELLER, ERIS SPIROLLARI, ANISHA M. CHANDY, SIMON J. HANFT, CHIRAG D. GANDHI and MEENA JHANWAR-UNIYAL

Anticancer Research November 2024, 44 (11) 4677-4690; DOI: https://doi.org/10.21873/anticanres.17295
Open Access
Systemic Inflammation Indexes and Risk of Immune-related Adverse Events in Patients With Metastatic Urothelial Carcinoma Treated With Immunotherapy
MICHELE DIONESE, DAVIDE BIMBATTI, FRANCESCO PIERANTONI, ELEONORA LAI, ELISA ERBETTA, NICOLÒ CAVASIN, SALIM JUBRAN, UMBERTO BASSO and MARCO MARUZZO

Anticancer Research October 2024, 44 (10) 4379-4386; DOI: https://doi.org/10.21873/anticanres.17267

Main menu

User menu

Search

Immunotherapy

Pages